Kit ELISA NOV sandwich (human): quantitative determination of Hu NOV in serum, plasma or cell culture medium. The test recognizes only the natural and recombinant forms of Hu NOV.
Accession number
P48745
Dose range
0.041-30 ng/ml
Sensitivity of the dosage
2 pg/ml
Calibration range
2 pg/ml to 30 ng/ml
Dose
ELISA solid-phase sandwich
Brand
Invitrogen
Kit ELISA NOV sandwich (human): quantitative determination of Hu NOV in serum, plasma or cell culture medium. The test recognizes only the natural and recombinant forms of Hu NOV.
Kit ELISA NOV sandwich (human): quantitative determination of Hu NOV in serum, plasma or cell culture medium. The test recognizes only the natural and recombinant forms of Hu NOV.
Method principle: This ELISA solid phase sandwich test (immuno-enzymatic dose) measures the amount of target bound between a pair of matched antibodies. A specific target antibody is pre-adsorbed into the wells of the supplied microplate. Samples, standards or controls are added to these wells and bind to immobilized antibodies (capture antibodies). The sandwich is formed by adding the second antibody (detection antibody), then a substrate solution reacts with the enzyme-antibodies-target complex to produce a measurable signal. The intensity of this signal is directly proportional to the concentration of the target present in the original sample.
Rigorous validation: Each batch manufactured from this ELISA kit is checked for criteria such as sensitivity, specificity, accuracy and reproducibility from one batch to another (see the package leaflet for more information on validation).
The NCC gene family (CTGF / Cyr61 / NOV) currently consists of six distinct members, which encode proteins involved in fundamental biological processes such as cell proliferation, adhesion, migration, differentiation, wound healing, langiogenesis, and several pathologies, including fibrosis and tumorigenesis. While Cyr61 and CTGF act as positive regulators of cell growth, nov (overexpressed nephroblastoma, CCN3 or NOVH) provides the first example of a CCN protein with negative regulatory properties and the first example of outright expression associated with tumour development. In animals and humans, increased nov expression is detected in tissues where calcium is a key regulator, such as the adrenal gland, as well as in the central nervous system, bones and cartilage, heart muscle and kidneys. The protein nov s-associated with the extracellular domain Notch1 and inhibits myoblast differentiation via the Notch signaling pathway.